Literature DB >> 25346143

Expression of nucleic acid-sensing Toll-like receptors predicts HPV16 clearance associated with an E6-directed cell-mediated response.

Mark E Scott1, Yifei Ma, Sepideh Farhat, Anna-Barbara Moscicki.   

Abstract

Toll-like receptors (TLRs), important in rapid clearance of incident human papillomavirus (HPV) infections, may also be important in shaping the adaptive response to persistent infections. We examined here the association between TLR expression and clearance of HPV16 infections following periods of persistence, using longitudinal TLR measurements and a time-to-clearance analysis, as well as the interaction between TLRs and adaptive, cell-mediated responses involved in clearance. TLR2, TLR3, TLR7, TLR8 and TLR9 mRNA expression were measured in cervical cytobrush samples by quantitative PCR. Responses to the HPV16 E6 and E7 oncoproteins were measured by an interferon-γ immunospot assay. Bivariable and multivariable Cox proportional hazard models were used to estimate the effect of TLRs on HPV16 clearance. Higher expression of TLR3 or TLR7 at an HPV16-positive visit was a significant (p ≤ 0.05) predictor of clearance by the following visit, in both unadjusted and adjusted (for smoking and oral contraceptive use) models. In women with, but not those without, a positive response to E6, higher expression of TLR3 (hazard ratio: 1.2 [95% confidence interval: 1.04-1.39], p = 0.012), TLR7 (1.39 [1.14-1.7], p = 0.001), TLR8 (1.37 [1.11-1.69], p = 0.003), or TLR9 (1.53 [1.13-2.08], p = 0.006) was significantly associated with clearance, revealing an important link between innate and adaptive immunity in the control of HPV infections following periods of persistence.
© 2014 UICC.

Entities:  

Keywords:  Toll-like receptors; cell-mediated immunity; cohort study; human papillomavirus infection; women

Mesh:

Substances:

Year:  2014        PMID: 25346143      PMCID: PMC4355215          DOI: 10.1002/ijc.29283

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  43 in total

1.  Improved amplification of genital human papillomaviruses.

Authors:  P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  EBV latent membrane protein 1 is a negative regulator of TLR9.

Authors:  Ikbal Fathallah; Peggy Parroche; Henri Gruffat; Claudia Zannetti; Hanna Johansson; Jiping Yue; Evelyn Manet; Massimo Tommasino; Bakary S Sylla; Uzma A Hasan
Journal:  J Immunol       Date:  2010-10-27       Impact factor: 5.422

Review 3.  Innate control of adaptive immunity: dendritic cells and beyond.

Authors:  Heung Kyu Lee; Akiko Iwasaki
Journal:  Semin Immunol       Date:  2007-02-05       Impact factor: 11.130

4.  Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone.

Authors:  Jeffrey Pudney; Alison J Quayle; Deborah J Anderson
Journal:  Biol Reprod       Date:  2005-08-10       Impact factor: 4.285

5.  Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method.

Authors:  P E Gravitt; C L Peyton; R J Apple; C M Wheeler
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

6.  High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression.

Authors:  Jeanette Reiser; José Hurst; Maike Voges; Peter Krauss; Peter Münch; Thomas Iftner; Frank Stubenrauch
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

7.  Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells.

Authors:  Gersende Caron; Dorothée Duluc; Isabelle Frémaux; Pascale Jeannin; Catherine David; Hugues Gascan; Yves Delneste
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

8.  Validation of reference genes in cervical cell samples from human papillomavirus-infected and -uninfected women for quantitative reverse transcription-PCR assays.

Authors:  Ibrahim I Daud; Mark E Scott
Journal:  Clin Vaccine Immunol       Date:  2008-07-16

9.  The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter.

Authors:  Uzma A Hasan; Claudia Zannetti; Peggy Parroche; Nadège Goutagny; Marine Malfroy; Guillaume Roblot; Christine Carreira; Ishraq Hussain; Martin Müller; Joyce Taylor-Papadimitriou; Didier Picard; Bakary S Sylla; Giorgio Trinchieri; Ruslan Medzhitov; Massimo Tommasino
Journal:  J Exp Med       Date:  2013-06-10       Impact factor: 14.307

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  9 in total

Review 1.  Early Defensive Mechanisms against Human Papillomavirus Infection.

Authors:  Andrea Moerman-Herzog; Mayumi Nakagawa
Journal:  Clin Vaccine Immunol       Date:  2015-06-10

2.  Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.

Authors:  Diane M Da Silva; Andrew W Woodham; Joseph G Skeate; Laurie K Rijkee; Julia R Taylor; Heike E Brand; Laila I Muderspach; Lynda D Roman; Annie A Yessaian; Huyen Q Pham; Koji Matsuo; Yvonne G Lin; Greg M McKee; Andres M Salazar; W Martin Kast
Journal:  Clin Immunol       Date:  2015-09-08       Impact factor: 3.969

3.  Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.

Authors:  Robert L Ferris; Nabil F Saba; Barbara J Gitlitz; Robert Haddad; Ammar Sukari; Prakash Neupane; John C Morris; Krzysztof Misiukiewicz; Julie E Bauman; Moon Fenton; Antonio Jimeno; Douglas R Adkins; Charles J Schneider; Assuntina G Sacco; Keisuke Shirai; Daniel W Bowles; Michael Gibson; Tobenna Nwizu; Raphael Gottardo; Kristi L Manjarrez; Gregory N Dietsch; James Kyle Bryan; Robert M Hershberg; Ezra E W Cohen
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777

Review 4.  Roles of Toll-Like Receptor 3 in Human Tumors.

Authors:  Xin Zheng; Song Li; Hui Yang
Journal:  Front Immunol       Date:  2021-04-27       Impact factor: 7.561

Review 5.  Subversion of Host Innate Immunity by Human Papillomavirus Oncoproteins.

Authors:  Irene Lo Cigno; Federica Calati; Silvia Albertini; Marisa Gariglio
Journal:  Pathogens       Date:  2020-04-17

6.  Innate immunity and HPV: friends or foes.

Authors:  Rafaella Almeida Lima Nunes; Mirian Galliote Morale; Gabriela Ávila Fernandes Silva; Luisa Lina Villa; Lara Termini
Journal:  Clinics (Sao Paulo)       Date:  2018-10-11       Impact factor: 2.365

7.  Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment.

Authors:  Paweł Łaniewski; Haiyan Cui; Denise J Roe; Dana M Chase; Melissa M Herbst-Kralovetz
Journal:  NPJ Precis Oncol       Date:  2020-08-03

Review 8.  High-Risk Human Papillomavirus and Epstein-Barr Virus Coinfection: A Potential Role in Head and Neck Carcinogenesis.

Authors:  Rancés Blanco; Diego Carrillo-Beltrán; Alejandro H Corvalán; Francisco Aguayo
Journal:  Biology (Basel)       Date:  2021-11-26

Review 9.  Human Papillomaviruses Target the DNA Damage Repair and Innate Immune Response Pathways to Allow for Persistent Infection.

Authors:  Elona Gusho; Laimonis Laimins
Journal:  Viruses       Date:  2021-07-17       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.